《Table 1 Baseline characteristics before conbercept injection in all subjects》

《Table 1 Baseline characteristics before conbercept injection in all subjects》   提示：宽带有限、当前游客访问压缩模式
本系列图表出处文件名：随高清版一同展现
《Intravitreal conbercept injection for neovascular agerelated macular degeneration》


  1. 获取 高清版本忘记账户？点击这里登录
  1. 下载图表忘记账户？点击这里登录

Sixty-six eyes of 63 patients were treated with intravitreal conbercept injections for neovascular AMD during the study period.All subjects were treated with a loading dose of 3monthly conbercept injections followed by a PRN protocol and no patients were lost in the core period of treatment.Baseline characteristics of the patients at the time of conbercept initiation are summarized in Table 1.The average time from illness onset to the injection was 7.4±9.4mo，with different length of 1wk to 4y.There were 11 patients combined with diabetes（without obvious diabetic retinopathy），17 patients had high blood pressure，6 people had both of diabetes and high blood pressure，1 patient underwent cardiac surgery and 3cases had cataract surgery.

图表编号XD0032753300    严禁用于非法目的
绘制时间2019.02.18
作者Bing-Hui Wu、Bing Wang、Hui-Qin Wu、Qin Chang、Hui-Qin Lu
绘制单位Department of Ophthalmology, Xi’an No.1 Hospital、Department of Ophthalmology, Xi’an No.1 Hospital、Department of Ophthalmology, Xi’an No.1 Hospital、Department of Ophthalmology, Xi’an No.1 Hospital、Department of Ophthalmology, Xi’an No.1 Hospital
更多格式高清、无水印（增值服务）

相关图表

  1. 《Table 1.Baseline characteristics.》2019.10.28
  2. 《Table 2 Baseline characteristics》2019.08.21
  3. 《Table 1 The baseline characteristics of patients》2019.05.21
  4. 《Table 1 Characteristics of the patients at baseline》2019.05.21
  5. 《表1 倾向值匹配前后的一般情况比较Tab 1 Baseline characteristics before and after propensity score matching》2019.02.28
  6. 《Table 6 Absolute standardized differences in baseline characteristics before and after propensity score matching》2019.04.27
  7. 《Table 6 Absolute standardized differences in baseline characteristics before and after propensity score matching》2019.04.27
  8. 《Table 1 Baseline characteristics》2019.04.27
  9. 《Table 1.Patients'Baseline Clinical Characteristics[Case (%) ]》2019.01.01
  10. 《Table 1.Baseline characteristics in MDS and control group》2019.02.20
  11. 《Table 1.baseline characteristics of patient》2019.02.20
  12. 《Table 1.baseline characteristics of patient》2019.02.20
  13. 《Table 1 The baseline characteristics of the two groups》2019.04.20
  14. 《Table 1 Baseline characteristics》2019.01.15
  15. 《Table 2 BCVA and CMT after conbercept injection in different times of 48 eyes》2019.02.18
  16. 《Table 1 Demographic and baseline characteristics of patients》2019.02.18
  17. 《Table 1 The comparison of baseline characteristics between twogroups》2019.01.18
  18. 《Table 1 Patients’demographic information and baseline characteristics》2019.01.18
  19. 《Table 1 Comparison of baseline characteristics (n=50, unit:case)》2018.03.10
  20. 《Table 1.Baseline characteristics for 67 patients with CTPV.》2018.12.15

随机翻阅

《表1 LCC主要参数：混合级联多端直流输电系统的功率协调控制策略》 《表1 变量定义：组织冗余、风险承担与研发投入》 《表1 两组患者治疗效果对比[例(%))》 《表4 不同生态廊道功能区区天然植被生态需水量》 《表1 银行1与银行2关于是否发放绿色信贷的博弈状况表》 《表2 两组患者治疗前后日常生活能力评分比较(±s,分)》 《表3 初馏塔及常压塔的操作温度》 《表2 11例患者移植情况及结果》 《表2 各组大鼠血铅和肝铅含量》 《表3 试验期间天气及降雨情况》